Navigation Links
Treating Epilepsy - The Next Big Thing
Date:6/30/2017

HIGH POINT, N.C., June 29, 2017 /PRNewswire/ -- Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing drug delivery innovations for developing improved novel formulations and alternative dosage forms of existing biologically active molecule.

Subveta oral spray for transmucosal delivery is based on our waterless self-nano emulsifying formula, which is designed to prevent precipitation of the active ingredient after contact with saliva. We believe the spray will provide fast onset of action and is designed to optimize drug absorption through the oral mucosa.
Subveta oral spray for transmucosal delivery is based on our waterless self-nano emulsifying formula, which is designed to prevent precipitation of the active ingredient after contact with saliva. We believe the spray will provide fast onset of action and is designed to optimize drug absorption through the oral mucosa.
Axium is patent pending not only on the use of Truveta (Lorazepam) administered intranasally, but also a new intranasal administration product that is highly accurate, reproducible and convenient for delivery of one or more predetermined unit doses of Lorazepam in the form of a nasal spray delivery system.
Axium is patent pending not only on the use of Truveta (Lorazepam) administered intranasally, but also a new intranasal administration product that is highly accurate, reproducible and convenient for delivery of one or more predetermined unit doses of Lorazepam in the form of a nasal spray delivery system.

Axium's pharmaceutical products are developed using highly effective technologies and demonstrated usefulness in the improvement of bioavailability and biological action of incorporated molecules. The company's product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes. Axium is working closely with clinicians, patient advocate groups, and universities worldwide to identify existing health issues where Axium's approach will be most beneficial for patient care.

Axium is patent pending not only on the use of Truveta (Lorazepam) administered intranasally, but also a new intranasal administration product that is highly accurate, reproducible and convenient for delivery of one or more predetermined unit doses of Lorazepam in the form of a nasal spray delivery system.

The objective is to produce the relatively rapid onset of a therapeutic effect and the moderate duration of therapeutic activity, with minimal side effects and improved bio-availability.

Furthermore, the system's delivery method is designed to be safe and easy, producing minimal physical discomfort and anxiety to the patient.

The medication is delivered through a small, inexpensive, manually operated and disposable device, and will be prepared under aseptic conditions; no significant residue is left in the delivery device following administration.

The FDA has accepted an orphan designation request for the intranasal lorazepam, (Truveta) administered intranasally in the Treatment of Lennox-Gastaut syndrome using the formulation that Axium is developing.

Orphan drug designation will provide the following benefits, protocol assistance offered by FDA, tax credits of 50 percent of the clinical drug testing cost awarded upon approval, waiver of NDA/BLA application, waiver of NDA/BLA application fee this is a $2.2 million value and, and the designation would give Axium a seven-year market exclusivity for the sale of Truveta, among many other advantages.

Axium plans to soon be publicly traded. Keep checking the website for updates. www.axium-pharma.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Related Images

image1.jpg

image2.jpg

Related Links

AXIUM PHARMACEUTICALS INC.

Technology / Pipeline

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/treating-epilepsy---the-next-big-thing-300482173.html


'/>"/>
SOURCE Axium Pharmaceuticals Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. AXONs Tau Vaccine Offers Potential for Treating Frontotemporal Dementia Patients
2. Research on Treating Sleep Apnea with Adaptive Servo-ventilation Published in the Journal of the American College of Cardiology (JACC)
3. Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
4. Entest BioMedical Inc.s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs
5. RegeneRx Receives Notice of Intent to Grant Patent in EU for Treating Neural Injury with Thymosin Beta 4
6. Geisinger study finds opioids not helpful in treating chronic pain
7. National Safety Council Applauds Centers for Disease Control and Prevention for releasing a prescribing guideline for treating chronic pain
8. Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome
9. Boston Scientific and Accenture Develop Data-Driven Digital Health Solution to Help Improve Patient Outcomes and Reduce Cost of Treating Chronic Cardiovascular Conditions
10. Dramatic Turn in Story of Invalidated 813 Patent For Treating Binge Eating Disorder as Owner Lucerne Biosciences Provides Patent Board Profile of itself and its High 40-75% Misrepresentation Rate
11. A Breakthrough Discovery on Treating Resistant Biofilm Infections Was Presented January 12 at Medtech Showcase in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, ... 8th Day Software and Consulting, LLC , and named ... 8th Day Software, based in Tennessee , ... 8th Day expands EnvoyHealth,s service offerings for health care ... "In an interoperable ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... property taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, ... many overseas retirement havens have extremely low property-tax rates, which contributes to the ...
Breaking Medicine News(10 mins):